Search Results for: lung cancer

QIAGEN continues to expand personalized health care portfolio and content menu for modules of the QIAsymphony automation platform.

The methods include the amplification of DNA or RNA fusion polynucleotides from patient blood, tissue, or cells and the determination of a therapeutic regimen based on the presence of the fusion in the sample.

CLP recently spoke with David Hout, PhD, VP of R&D, Insight Genetics, about continuing work on the Insight ALK Screen, Insight ALK Resistance, and other biomarker-specific diagnostic tools to advance cancer care.

Ronnie Andrews, Life Technologies’ president of medical sciences, has shepherded multiple acquisitions and product launches as Life continues to expand its presence in the world of clinical diagnostics. Here he looks back at 2012, and ahead to 2013.